Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1Esophageal Squamous Cell Carcinoma 1

Interventions

Specimen Handling 79Bevacizumab 66Drug Therapy 65Cisplatin 64Carboplatin 63Magnetic Resonance Spectroscopy 61Radiotherapy 57Cyclophosphamide 55Gemcitabine 54pembrolizumab 53Oxaliplatin 50Capecitabine 50toripalimab 42Paclitaxel 41tislelizumab 40Standard of Care 40Biopsy 37fludarabine 36Fluorouracil 35venetoclax 33Injections 33Blood Specimen Collection 31Immune Checkpoint Inhibitors 30anlotinib 29Nivolumab 29Surgical Procedures, Operative 28Irinotecan 27Docetaxel 27Dexamethasone 27Leucovorin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × ivarmacitinib × 1 year × Clear all
NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Data powered by HemOnc (CC BY 4.0) Colophon âš¡